Molecular Mechanisms of Arterial Calcification Disorders

Arterial calcification is now recognised as a regulated, cell-mediated process rather than a passive deposition of calcium phosphate. Under pathological conditions—such as chronic kidney disease, diabetes and genetic disorders—vascular smooth muscle cells and perivascular fibroblasts undergo phenotypic switching towards osteogenic and chondrocytic lineages, driven by transcription factors including Runx2 and Msx2. This shift is accompanied by the release of matrix vesicles and extracellular vesicles that nucleate hydroxyapatite crystals within the extracellular matrix. A delicate balance between pro-calcifying factors (bone morphogenetic proteins, alkaline phosphatase activity) and anti-calcifying molecules (inorganic pyrophosphate, matrix Gla protein) governs mineral deposition. Key molecular regulators include ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), which generates inorganic pyrophosphate from extracellular ATP, and the ATP-binding cassette transporter ABCC6, which influences systemic pyrophosphate levels. Dysregulation of matrix metalloproteinases and their inhibitors remodels the elastic fibre network, altering tissue stiffness and promoting local mineralisation. Together, these processes underpin both monogenic syndromes—such as generalised arterial calcification of infancy and pseudoxanthoma elasticum—and the widespread arterial stiffening seen in ageing populations, underscoring an urgent need for targeted molecular therapies.

Research from Nature Portfolio

Recent studies have characterised how resident fibroblasts dictate local calcification in pseudoxanthoma elasticum. Comparative analysis of fibroblast secretomes from calcification-prone versus unaffected dermis revealed that pro- and anti-calcifying proteoglycans, glycoproteins and an imbalance of matrix metalloproteinases and their inhibitors generate microenvironments that either stabilise elastic fibres or render them susceptible to mineral deposition. These findings highlight fibroblasts as active architects of tissue remodelling and calcification. In foundational work using animal models of generalised arterial calcification of infancy, subcutaneous administration of an ENPP1-Fc fusion protein restored systemic pyrophosphate levels, prevented arterial mineralisation and rescued survival. This fusion protein approach demonstrates the therapeutic potential of enzyme replacement strategies to correct the underlying metabolic defect and halt progression of vascular calcification.

Molecular Mechanisms of Arterial Calcification Disorders publication trend

The graph below shows the total number of articles in molecular mechanisms of arterial calcification disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Ectopic calcification: Pathological deposition of calcium phosphate crystals in soft tissues.

Inorganic pyrophosphate (PPi): A small molecule that inhibits hydroxyapatite formation and regulates mineralisation.

Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1): An enzyme that hydrolyses extracellular ATP to generate pyrophosphate and AMP.

Extracellular matrix (ECM): The network of proteins and polysaccharides that provides structural support and biochemical signals to cells.

Matrix metalloproteinases (MMPs): A family of proteolytic enzymes that degrade extracellular matrix components and modulate tissue remodelling.

Nuclear factor erythroid 2-related factor 2 (Nrf2): A transcription factor regulating antioxidant responses and certain genes involved in mineralisation control.

References

1. ENPP1 in Blood and Bone: Skeletal and Soft Tissue Diseases Induced by ENPP1 Deficiency. Annual Review of Pathology Mechanisms of Disease (2023).
2. Activation of Nuclear Factor Erythroid 2-Related Factor 2 Transcriptionally Upregulates Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Expression and Inhibits Ectopic Calcification in Mice. Antioxidants (2024).
3. Fibroblasts’ secretome from calcified and non-calcified dermis in Pseudoxanthoma elasticum differently contributes to elastin calcification. Communications Biology (2024).
4. Matrix Metalloproteinases Contribute to the Calcification Phenotype in Pseudoxanthoma Elasticum. Biomolecules (2023).
5. ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy. Nature Communications (2015).